Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 581 to 590 of 858 total matches.
Growth Hormone for Normal Short Children
The Medical Letter on Drugs and Therapeutics • Nov 10, 2003 (Issue 1169)
Meinertz, M.D., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F ...
The FDA has approved Humatrope, Lilly's brand of recombinant human growth hormone (somatropin), for long-term treatment of children with idiopathic, non-growth-hormone-deficient (NGHD) short stature who are more than 2.25 standard deviations below the mean height for their age and sex. This review describes the clinical studies, adverse effects, and includes a cost table for other brands of somatropin.
Folic Acid Supplementation to Prevent Neural Tube Defects
The Medical Letter on Drugs and Therapeutics • Mar 01, 2004 (Issue 1177)
Meinertz, M.D., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F ...
Many women of child-bearing age now take folic acid supplements of 400 ╡g per day to prevent neural tube defects in their offspring (Medical Letter 1998; 40:75). An FDA advisory committee has recommended development of a combination tablet containing an oral contraceptive and 400 ╡g of folic acid. A recent editorial in the New England Journal of Medicine suggested that folic acid doses should be higher (NJ Wald, N Engl J Med 2004; 350:101).
Prevention and Treatment of Sunburn
The Medical Letter on Drugs and Therapeutics • Jun 07, 2004 (Issue 1184)
Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
Solar ultraviolet (UV) light capable of injuring the skin is classified by wavelength into UVA I (340-400 nm), UVA II (320-340 nm) and UVB (290-320 nm). UVB is responsible for most of the erythema of sunburn. UVA has been implicated in the development of phototoxicity and photoaging. The FDA permits sunscreen manufacturers to claim broad-spectrum protection if their products block at least part of UVA II in addition to UVB.
Click here to view the free full article.
Click here to view the free full article.
Conductive Keratoplasty (CK) for Presbyopia
The Medical Letter on Drugs and Therapeutics • Jun 21, 2004 (Issue 1185)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
The ViewPoint CK System (Refractec) for conductive keratoplasty (CK), previously approved by the FDA as a device for treatment of hyperopia (farsightedness), was recently approved for treatment of presbyopia (age-associated loss of ability to view near objects).
Methamphetamine Abuse
The Medical Letter on Drugs and Therapeutics • Aug 02, 2004 (Issue 1188)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
Methamphetamine, a highly addictive synthetic sympathomimetic, has again become important as a drug of abuse in the US. Its resurgence has been associated with unsafe sexual practices that have resulted in an increase in HIV transmission, particularly among men who have sex with men (SJ Semple et al, J Subst Abuse Treat 2002; 22:149; A Urbina and K Jones, Clin Infect Dis 2004; 38:890).
Trospium (Sanctura): Another Anticholinergic for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • Aug 02, 2004 (Issue 1188)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
Trospium chloride (Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available in Europe for many years.
COX-2 Alternatives and GI Protection
The Medical Letter on Drugs and Therapeutics • Nov 08, 2004 (Issue 1195)
of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New York ...
With the removal of Vioxx from the market and concerns about cardiovascular toxicity with other selective COX-2 inhibitors, patients are looking for safe alternatives, and manufacturers of other drugs are looking for additional market share. The COX-2 inhibitors first became popular because they have less upper GI toxicity than older less selective NSAIDs, at least in the short term, in patients not taking aspirin.
Acetylcysteine (Acetadote) for Acetaminophen Overdosage
The Medical Letter on Drugs and Therapeutics • Aug 15, 2005 (Issue 1215)
., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D ...
Acetaminophen (paracetamol; Tylenol, and others) taken in overdosage can cause severe hepatic injury and death. Acetaminophen poisoning is treated with (N-)acetylcysteine. Available for many years in the US as a solution for inhalation therapy (Mucomyst, and others), it subsequently became available for oral use and was recently marketed in the US for intravenous (IV) use as Acetadote (Cumberland).
InstaRead Lithium System
The Medical Letter on Drugs and Therapeutics • Oct 10, 2005 (Issue 1219)
, Copenhagen
Dan M. Roden, M.D., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University ...
The InstaRead Lithium System (ReliaLAB), an office test that only requires a finger stick to measure lithium serum concentrations, has been cleared by the FDA and is now available. Standard methods for measuring lithium serum concentrations require venipuncture and transport of the specimen to commercial laboratories.
Nelarabine (Arranon) for T-Cell Acute Lymphoblastic Leukemia
The Medical Letter on Drugs and Therapeutics • Feb 13, 2006 (Issue 1228)
., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D ...
Nelarabine (Arranon - GlaxoSmithKline), a prodrug of the deoxyguanosine analog 9-β-D-arabinofuranosylguanine (ara-G), has been approved by the FDA for treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to, or has relapsed following, treatment with at least two chemotherapy regimens.